BioSpace News Archive

If approved, SPRAVATO™ will offer the first new mechanism of action in 30 years to treat this debilitating disease, continuing Janssen’s 60-plus-year history and commitment to research that make a difference for people living with mental illnesses, including severe mood disorders

In a Valentine’s Day survey conducted by Xperience Days on over 500 Americans regarding gift-giving habits, half of the respondents revealed they’re not as excited about the holiday as they once were.

Harmony Biosciences, LLC announced that the U.S. Food and Drug Administration has accepted for filing the New Drug Application for its investigational product, pitolisant, and has granted Priority Review for this NDA.

Natural Alternatives International, Inc. announced net income of $2.2 million, or $0.31 per diluted share, on net sales of $36.0 million for the quarter ended December 31, 2018.

Poseidon Water CEO Carlos Riva today issued a statement in response to Governor Gavin Newsom’s State of the State Address.

Cartherics Pty Ltd and panCELLa Inc. are pleased to announce their collaboration to research, develop and commercialize products for the treatment of cancer and other debilitating diseases using cell therapy.

State Representative Jeff Shipley (R-Fairfield) has introduced two bills related to rescheduling psilocybin, and other potential medicines, for clinical use.

Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced the appointment of Brian Di Donato to the position of Senior Vice President and Chief Financial Officer, effective immediately.

Running a seamless clinical trial means improving not only data quality but also operational logistics and most importantly the patient experience.

VUB, the Vrije Universiteit Brussel, and eTheRNA immunotherapies, a clinical-stage company developing cancer immunotherapies based on its proprietary mRNA-based TriMix platform, announce the recruitment of the first patient for a collaborative TriMix-BRE study to investigate the effect of the TriMix product as neo-adjuvant treatment (treatment before planned surgery) for breast cancer patients.